Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03496467 · ClinicalTrials.gov registry record · Phase 2

Safety/Efficacy of Nepafenac Punctal Plug Delivery System Compared to Placebo to Control Ocular Pain/Inflammation After Cataract

A Phase 2 study of Pain and Inflammation, sponsored by Mati Therapeutics.

Completed
Registry status
Phase 2
Development phase
56
Enrollment target
3
Study locations

NCT03496467: Completed Phase 2 study of Pain and Inflammation, sponsored by Mati Therapeutics.

NCT03496467 is a Phase 2 study of Pain and Inflammation that has completed, run by Mati Therapeutics. The registered enrollment target is 56 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (82% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT03496467, a Phase 2 study of Pain and Inflammation, has completed, sponsored by Mati Therapeutics.

COMPLETED
Registry status
Phase 2
Development phase
56 participants
Enrollment target
3
Study locations

Study Summary

This is a Phase 2, multi-center, randomized, parallel-arm, double-masked, placebo-controlled study. One (1) to 2 days prior to their scheduled cataract surgery, each study subject will be randomized (2:1) in to one of two treatment groups: N-PPDS or p-PPDS, which are inserted in the lower punctum of the subject's scheduled surgical eye. All plugs will remain in the study subject's lower punctum for a period of 2 weeks following cataract surgery.

Primary Outcome

Assessment of pain in subjects as measured by a scale of 0 - 5. Post-op pain scale: 0 represents absence of pain and 5 represents a definite, continuous unbearable ocular or periocular pain.

Conditions Studied

Interventions

  • COMBINATION_PRODUCT Nepafenac PPDS
  • COMBINATION_PRODUCT Placebo PPDS

Study Locations (3)

Kentucky

  • Cincinnati Eye Institute-Edgewood - Edgewood

New York

  • Ophthalmic Consultants of Long Island - Garden City

South Carolina

  • Kerry Solomon, MD - Mt. Pleasant

Trial Details

FieldValue
Enrollment Target 56 participants
Start Date 2018-03-05
Est. Completion 2018-12-17
Phase Phase 2
Mati Therapeutics

12 total trials

What the finished NCT03496467 record still lists

NCT03496467 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 304-participant average among 374 other Pain trials with a reported enrollment target (82% lower).

The record links to 2 conditions, with Pain appearing as the primary indexed condition, and to 2 interventions - of which Nepafenac PPDS is the first listed.

NCT03496467 reports a single indexed study location in Kentucky, New York, South Carolina.

Frequently Asked Questions

What is clinical trial NCT03496467 about?

NCT03496467 is a clinical study titled "Safety/Efficacy of Nepafenac Punctal Plug Delivery System Compared to Placebo to Control Ocular Pain/Inflammation After Cataract". This is a Phase 2, multi-center, randomized, parallel-arm, double-masked, placebo-controlled study. One (1) to 2 days prior to their scheduled cataract surgery, each study subject will be randomized (2:1) in to one of two treatment groups: N-PPDS or p-PPDS, which are inserted in the lower punctum of...

What is the current status of trial NCT03496467?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2018-03-05. Estimated completion is 2018-12-17.

What conditions does trial NCT03496467 study?

This clinical trial studies the following conditions: Pain, Inflammation.

What interventions are being tested in trial NCT03496467?

The interventions under investigation include: Nepafenac PPDS (COMBINATION_PRODUCT), Placebo PPDS (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT03496467?

This trial is sponsored by Mati Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03496467 being conducted?

This trial has 3 study locations across Kentucky, New York, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03496467's enrollment target sits among peer trials

56 245th of 374 higher than 127 of 374 other Pain trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02287428 · 56 participants · Phase 1

    Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM

  • NCT02923011 · 56 participants · Phase 3

    Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas

  • NCT02935283 · 56 participants

    Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders

  • NCT03375866 · 56 participants · NA

    Effects of Mixed Nut Consumption on Satiety and Weight Management

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03496467, the US trial registry maintained by the National Library of Medicine. NCT03496467 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.